Disclosed is a method of manufacturing a medium composition for cell culture, and a method of manufacturing a crushed stem cell extract using a method of manufacturing a medium composition for cell culture and a 3-low extracting method of active ingredients of a stem cell. The medium composition for cell culture includes a basal medium; a hyaluronic acid; and an additive composition. According to an embodiment, when active ingredients of a stem cell are extracted, a stem cell is crushed at a 3-low circumstance of low temperature, low pressure, a hypotonic circumstance.

A pharmaceutical composition for treating leukemia, including by weight 2 to 8% of realgar, 25 to 42% of indigo naturalis, 50 to 60% of salvia miltiorrhiza, and 6 to 10% of heterophylla.

A sustained-release preparation containing pseudoephedrine is provided comprising pseudoephedrine or a pharmaceutically acceptable salt thereof, and a hardened oil or stearic acid. The sustained-release preparation containing pseudoephedrine may contain a hardened oil or stearic acid in an amount of 100% by mass to 500% by mass with respect to the content of the pseudoephedrine or a pharmaceutically acceptable salt thereof. In addition, the sustained-release preparation containing pseudoephedrine may have a first part and a second part, the first part may contain the pseudoephedrine or a pharmaceutically acceptable salt thereof, and the first part or the second part may contain an optional active ingredient.

Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) (baclofen) and its pharmaceutically acceptable salts.

Oxidative stress is linked to several health conditions including, without limitation, cancer, aging, neurodegenerative and metabolic diseases. Increased levels of oxidative stress may result from increased exposure to radiation or other environmental stressors and/or diminished protective effects of cellular defenses against reactive oxygen species. The present disclosure provides compositions and methods comprising encapsulated cannabinoid compounds useful for reducing oxidative stress in a subject.

Compositions for the immediate release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids and one or more intra-granule excipients. Alternatively, each particle may comprise the one or more cannabinoids and a porous bead core. The composition may be prepared by a method that involves combining the one or more cannabinoids with the one or more intra-granule excipients, and then granulating the combination, such as through fluid bed granulation, shear-induced wet granulation, or spray granulation. The composition may also be prepared by a method that involves mixing the one or more cannabinoids with a population of porous bead cores.

Food, beverage and nutritional supplements containing microparticles containing stabilised CBD oil, and methods for the production thereof Food, beverage and nutritional supplements that containing microparticles are described. The microparticles contain CBD oil stabilized in an acacia or inulin fibre or cyclodextrin matrix. Methods for the production of the compositions comprise making the microparticles by providing an oil-in-water microemulsion comprising CBD oil, water, acacia/inulin fibre and optionally maltodextrin or cyclodextrin, and freeze-drying the microemulsion to remove water and provide a preparation of dried microparticles. The dried microparticles comprise a dispersed phase of stabilized microdroplets of CBD oil disposed in a continuous solid matrix comprising acacia or inulin fibre. The preparation of microcapsules contains less than 10% free CBD oil and exhibit improved pharmacokinetics and bioavailability of CD.

The invention describes a modified release formulation comprising 2 to 10% withanolides, obtained from root powder of Withania somnifera. The formulation is comprised of at least one pH independent release controlling agent or the combination thereof. The invention also provides a process for preparation of modified release composition; wherein Ashwagandha root powder enriched with withanolides is uniformly dispersed and embedded throughout the matrix of at least one pH independent release controlling agent. The granules can be conveniently formulated in suitable compressible dosage forms, filled in sachets or capsules for oral administration. The formulation may release more than 75% of withanolides over a period of 6 to 12 hours. The modified release formulation may be useful for maintaining significant concentration of withanolides in blood plasma over extended time and can be administered to the subjects in need thereof for stress management, cognitive benefits and improving overall mental well-being.

The invention relates to novel liquid pharmaceutical compositions comprising (8)-8-[(methylthio)methyl]-6-propylergoline (pergolide) as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.

Provided are: a method for producing an oral composition suitable for treatment or prevention of a disease or symptom in the oral cavity; and an oral composition produced by the production method. The oral composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the oral composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.